Right now, everyone in the investment community is looking for the next DNDN (Dandreon Corp) FDA Approval play. Gerard Adams, President of Wall Street Grand LLC – an online Investor Newsletter stated “DNDN was one of the biggest pharma plays I have ever seen making an astronomical run from $2.95 to as high as $57.67 for a whopping gain of 1,855%. DNDN actually just hit its high this past Friday after receiving their FDA Approval.” Mr. Adams went on to state “I believe we have found the next pharma FDA Approval play in this red hot sector.”
Arrayit Corp (Arrayit Corporation ARYC.OB) has an extremely small float and once demand starts pouring in on Monday we could quickly see this new FDA Approval play make nice gains.
Gerard Adams stated “The main reason why I absolutely love Arrayit Corp is because of its 'OvaDx(TM)' which is a pre-symptomatic Ovarian Cancer test using its proprietary patented microarray technology.”
ARYC's OvaDx Pre-Symptomatic Ovarian Cancer Test will be the market's FIRST comprehensive diagnostic screen for ovarian cancer, and will be recommended for all women over the age of 35. OvaDx uses approximately 100 proteomic biomarkers in a microarray format to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as a result of the body's natural immune response to developing ovarian tumors. Upon FDA approval, OvaDx should have rapid adoption, accelerating revenue, earnings growth, and shareholder value significantly.
Conservative estimates are for revenues that could reach $1 billion dollars within 5 years for this test alone.
Having the best support in the business always helps a company on the fast track to success and that’s why Arrayit Corp announced that they appointed DOCRO, Inc. of Seymour, Connecticut, to assist in obtaining a 'Fast Track' FDA approval for OvaDx. DOCRO has steered nearly 100 In Vitro Diagnostic (IVD) clinical trials through the Food and Drug Administration in the past 12 years, along with 39 pre-market approval (PMA) and 46 510(k) applications. DOCRO has an unparalleled 99% success rate with the FDA.
Gerard Adams went on to state, “So you think DNDN was a big winner that you missed out on? In my opinion, ARYC is close to getting their FDA approval and once they do we believe long-term that ARYC could become even bigger than DNDN.”
Arrayit's microarray test, which detects both early and late stage ovarian cancer, leverages the company's patented microarray platform and distinguished 13-year track record as a microarray technology leader. ARYC has been around for 17 years but just did their merger a year ago so nobody even knows it exists. Talk about a hidden Gem.
On top of all of this, ARYC is also working on other Pre-Symptomatic tests for other diseases such as Parkinson, Prostate and Breast Cancer. On top of it all Arrayit Corp is the market leader in the Microarray Tech. having the #1 Position in the world.
Last week DNDN got their FDA Approval and already hit its high Friday for gains of 1,855% and a second pharma company Wall Street has been playing POZN also just got their FDA Approval after the close on Friday and is set to skyrocket on Monday. Once these pharma plays get their FDA Approval they tend to gap up big and traders that have been waiting for this breaking news now have the opportunity to take profits and start looking for the next FDA Approval investment opportunity. Investors like all humans are creatures of habit and follow strict disciplined trading rules for financial success. After what we have seen with DNDN and POZN investors will soon realize that ARYC is next up to bat, according to Gerard Adams.
You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com .Gerard@WallStreetGrand.com
About Wall Street Grand:
WallStreetGrand.com.com offers a newsletter covering companies traded on the OTC, OTCBB, PINKSHEETS and AMEX stock exchanges. Subscribers to our newsletter will receive up to date time sensitive press releases and profiles on featured companies traded on various small cap stock exchanges such as otc, otcbb, pinksheet and amex that we feel are undervalued prospects with significant upside potential. Other sectors we cover are: alternative energy stocks/companies (solar stocks, wind stocks, hydro stocks, nuclear stocks, uranium stocks, biofuel stocks, clean coal stocks) as well as oil and gas stocks, gold stocks and mining stocks.
WallStreetGrand.com focuses its energy on finding small- and micro-cap stocks that are in a position to produce high-yield returns. When discovered by our research analysts, these properly positioned companies are investigated in the fullest, with looks at past performance as well as an eye on the future. After a comprehensive discovery, any pertinent information is sent out to a select but expansive audience. Our newsletter is updated daily to give our members a reliable source of information on what's next on Wall Street.
Wall Street Grand takes pride in its ability to inform and connect with our extensive following. Our vast and diversified audience is comprised of a loyal collective group of market makers, savvy retail investors, institutional money managers, financial analysts, and brokers, all of whom are interested in unique investment opportunities.
Penny Stock research reports and investor relations are provided by WallStreetGrand.com, visitors to our web site can sign up for our penny stock newsletter and be updated when we begin coverage on new small cap companies. Penny Stocks trade in the Small Cap Market being informed is a critical component to making decisions. Penny Stock coverage is what WallStreetGrand.com covers and strives to keep you updated on companies looking to move ahead of the pack. Sign up today and allow WallStreetGrand.com to provide you with the latest research reports on penny stocks.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.
Disclaimer:
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. Never invest into a stock we discuss unless you are prepared to lose your entire investment.WSG has been compensated $25,000 and 150,000 restricted shares by Arrayit Corporation the company for an investor awareness campaign. WSG may or may not trade the stocks mentioned in this alert which can affect the price of the stock. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
